Universe Pharmaceuticals Seeks Shareholder Approval for 1-for-10 Reverse Split to Regain Nasdaq Compliance

summarizeSummary

Universe Pharmaceuticals filed proxy materials for its September 30, 2026 annual meeting, seeking approval for a conditional 1-for-10 reverse stock split and the re-election of five directors.

check_boxKey Events · Corporate Governance and Compliance · UPC

• Conditional 1-for-10 Reverse Split Proposed

  Shareholders will vote on a reverse split that triggers only if the Class A share price closes below $1.00 for three consecutive trading days within 12 months of the resolution date.

• Authorized Capital Reduction

  If approved, authorized shares would drop from 1.8 billion Class A and 200 million Class B to 180 million Class A and 20 million Class B, with par value rising from $0.00001 to $0.0001.

• Five Directors Up for Re-election

  The board recommends re-electing LAI Gang, YANG Lin, PANG Jiawen, ZHENG Ding, and YU Yongping to serve until the next annual meeting.

• Meeting Set for September 30, 2026

  The annual general meeting will be held in Ji'an, Jiangxi, China, with a record date of August 31, 2026; 5,008,313 Class A and 16,077 Class B shares were outstanding as of that date.

auto_awesomeAnalysis · UPC · Life Sciences

The company is asking shareholders to approve a 1-for-10 reverse stock split that would take effect only if the stock trades below $1.00 for three consecutive days within the next 12 months. With the stock at $4.27 today, the trigger is not imminent, but the proposal is a pre-emptive tool to address Nasdaq's minimum bid price requirement. The reverse split would reduce the outstanding Class A shares from roughly 5.0 million to about 500,000, which could increase volatility and make the stock harder to trade. The board is also seeking re-election of all five directors, a routine governance matter.